

Subject Index

- Acute lung injury 228
- Acute organ system failure (OSF) 211
- Acute respiratory failure 148, 228, 232
 - extracorporeal support 167–75
 - gas exchange in 169–73
 - lung model 168–9
 - rationale for extracorporeal support 170–1
- Adult respiratory distress syndrome (ARDS)
 - 123, 209
 - acute stage of 30
 - as cause of death 43
 - at-risk groups 228–9
 - biochemical changes in patients at risk from 67–77
 - clinical presentation 231
 - definitions 225–8
 - development of 33
 - diagnosis 211, 231–3
 - diagnostic criteria 68–9, 232
 - general principles of prognostic studies 209–15
 - Geneva scoring system 221–2
 - intensity of therapy 214
 - mechanisms of 33
 - mediators in 37, 67
 - morphology 21–31
 - outcome 214
 - pancreas, role in 67–77
 - pathogenesis of 21–3, 67
 - populations at risk of developing 227
 - post-traumatic 21–3, 27, 30
 - potential mediators 33
 - predisposing factors for development of 228
 - prevalence rates for 229
 - primary cause of death in 227
 - prognostic indices 215–17
 - progression towards 227
 - scoring system 219–23
 - severity indices 220–1
 - severity of illness 210–11
 - subacute or chronic stage 30
 - survival 226
 - use of term 43
 - white cell activation in 37–8
- Alveolar–arterial PO_2 gradient 51, 54, 59
- Alveolar gas mixing efficiency 149
- Alveolar infection 30
- Alveolar septum 22, 27
- Alveolar ventilation 166
- Amrinone 195
- Angiotensin 191
- Angiotensin converting enzyme (ACE) 74
- APACHE (Acute Physiologic And Chronic Health Evaluation) 209–11, 215, 216
- Arterial–alveolar nitrogen difference 153–6
- Arterial hypoxia 50
- Arterial oxygen content (CaO_2) 100
- Arterial oxygen delivery (DaO_2) 100, 106, 108, 109, 113, 114
 - and oxygen consumption
 - abnormalities in 101
 - normal relationship 100
- Arterial oxygen tension (PaO_2) 139
- Aspiration damage 22–3
- Antithrombin III (AT III) 69, 71, 75
- B**
- Basement membrane 6
- Beta-adrenergic receptors 195
- Bidirectional rotating valve tube 162
- Blood flow
 - maldistribution of 96
 - optimization 191
- Blood–gas barrier 22
- Blood gas measurements 164
- Blood sampling 69
- Blood transfusion 43
- Bronchial aerodynamics 159, 163
- C**
- C-reactive protein (CRP) 76
- Capillary filtration coefficient 15–16
- Cardiac index (CI) 80, 81, 84, 90, 100, 102, 103
 - methods of measuring 104
- Cardiac output 131
- Cardiac volume measurement 81–4
- Cardiogenic shock 198–200
- Cellular metabolic activity defect 97
- Central venous pressure 80, 81, 203
- Coagulation disorders 46
- Colloid osmotic forces 14

- Complement activation 36
 Compliance 12–13
 Compliance-independent ventilation 157–66
 Computerized tomographic (CT) scan 168–9
 “Continuous channel” theory 8
 Continuous positive airway pressure (CPAP)
 139, 144, 150–2, 155, 173, 226, 230
 Continuous positive pressure ventilation
 (CPPV) 167, 170, 171, 175
 Contractility 127, 130
 Convective ventilation 141
 Coronary blood flow 198
 Cytoprotection 116
 Cytotoxic mediators 96
- Diffusive mixing** 143–5
 Dobutamine 194, 195
 Dopamine 191, 194, 195
 Dopexamine 195
- Ejection fraction measurement 81–4
 End-diastolic volume (EDV) 86, 88
 Endothelial bleb formation 26
 Endothelial oedema 27
 Endothelium 4–5
 End-systolic volume (ESV) 86
 Epithelial cells 28, 29
 Extracorporeal circuit 172
 Extracorporeal carbon dioxide removal
 (ECCO₂R) 167, 171, 173–5
 Extracorporeal membrane lung oxygenation
 (ECMO) 167, 171, 174–5
- Fenestrae** 8–10
 “Ferry boat” theory 8
 Fibrin monomers 28
 Fibrinogen levels 46
 Fick equation 102, 103
 Filtration coefficients 9
 “Fission–fusion” theory 8
Fluid flux
 across microvascular endothelium 3–19
 transvascular 3–4
 Fluid replacement, role 179–90
 Fraction of inspired oxygen (FiO₂) 139, 143, 153,
 170, 173
 Functional residual capacity (FRC) 143–50
- Gas exchange in acute respiratory failure lung**
 169–73
 Gated blood pool scan 81, 88
 Global contractility 130
 Glycocalyx 5
- Haemodynamic concepts in septic shock** 79–93
 Hageman factor XII 73
- Haptoglobin concentrations 72
 High-frequency oscillation 157, 161
 High-frequency ventilation 157–66
 animal experiments 160, 163
 discussion of results 164–6
 endotracheal 162, 163, 165
 exciting systems 158
 inhomogeneities of ventilation 166
 jet 161, 164–5
 methods 158–60
 models 158
 results 161–4
 Histiotoxic hypoxia 97
 Humoral cascades 37, 38
 Hyaline membrane formation 29
 Hyaluronate coils 10
 Hydraulic conductance 9
 Hydrostatic pressure 15
 Hyperdynamic endotoxaemia 185–8
 Hypovolaemic-traumatic shock 24
- Immunoreactive trypsin (IRT)** 69, 70, 73–5
 Inhalation damage 22–3
 Inspiratory flow pattern 148–50
 Intercellular junctions 6–7
 Intermittent mandatory ventilation (IMV) 150,
 151
 Intermittent positive pressure ventilation
 (IPPV) 147–8
 Interstitial fluid 13
 Interstitial oedema 23, 25
 Interstitial pressure 11, 181
 Interstitium 10–11, 26
 Intra-aortic balloon counterpulsation (IABCP)
 197–201
 Intracranial pressure 203
 Intrapulmonary pressure 158, 161
 Intravascular platelet aggregates
 and postoperative hypoxia 50–3
 kinetics of 53–4
 measurement of 46–50
 methods of preventing formation of 62
 Intravascular pressure 181, 182
 Intravenous fluids 191
 Intraventricular pressure gradient 133
 Intraventricular septum 133
 Inversed I:E ratio 148–50
 Irreversible shock 43–4
- Kallikrein–kininogen–kinin (KKK) system** 67,
 72, 73, 75
- Left ventricular ejection fraction (LVEF)** 82, 83,
 84, 88, 89
Left ventricular end diastolic volume
 (LVEDV) 81–4
Left ventricular performance 123–4
 Leucostasis 25, 26

- Lobar ventilation 163–5
- Low-frequency positive pressure ventilation (LFPPV) 167, 171–5
- Lung
- in shock 24–5
 - ultrastructural alterations 24
- Lung damage
- extrathoracic 23
 - trauma-related indirect 23
- Lung function assessment 140–7
- Lung injury
- acute 33–41
 - direct 22
 - direct versus indirect 21–3
- Lung lymph flow 181, 182
- Lung mechanics 140–1
- Lung water content 181
- Lymphatic pumps 11–12
- Lymphatic vessels 11–12
- Macrocirculatory failure 179–80
- Mean airway pressure (MAWP) 170, 173
- Mechanical assistance devices 197–205
- Mephentermine 191
- Metaraminol 191
- Michaelis constants 99
- Michaelis–Menten law 99
- Microcirculatory blood flow 110
- Microcirculatory failure 179–80
- Microvascular endothelium, fluid flux across 3–19
- Multiple organ failure syndrome 95–121
- associated with sepsis and trauma 96–7
 - mechanisms contributing to development of 96–7
- Myocardial blood flow 127
- Myocardial depression 192–3
- in septic shock 86–9
- Myocardial oxygen consumption 198
- Myocardial perfusion 127, 129–33
- Neutrophils
- activation 37
 - pulmonary membrane damage by 38–9
- Nitrogen decay curve 145
- Nitrogen gradient 153–4
- Nitrogen shunt concept 154–5
- Noradrenaline 191
- Osmotic pressure 14
- Osmotic reflexion coefficient 14–15
- Oxygen concentration vs. oxygen consumption 99
- Oxygen consumption
- and arterial oxygen delivery (DaO_2)
 - abnormalities in 101
 - normal relationship 100
 - in the critically ill 95–121
 - interpretation of measurements of 105–13
 - measurement in the critically ill 102–5
 - vs. oxygen concentration 99
- Oxygen delivery in the critically ill 95–121
- Oxygen flux test 105–13
- interpretation of 113–14
- Oxygen toxicity 229–31
- Oxygen uptake index (OUI) 102, 105, 109, 113, 114
- Pancreas, role in ARDS 67–77
- Peclet number 141
- Peripheral vascular failure 89–90
- Perivascular oedema 27
- pH values 16
- Plasma colloid osmotic pressure 184
- Pneumatic anti-shock trousers 201–3
- Pneumocytes
- type I 28
 - type II 30
- Polymorphonuclear leucocyte (PMN) 25–6, 33–6, 38, 39
- Positive end-expiratory pressure (PEEP) ventilation 101, 109, 111, 123, 143, 144, 148, 149, 168, 170, 215, 226, 229–31
- cardiac output during 131
 - haemodynamic side effects of 123–9
- Postoperative hypoxia 50–3
- Postoperative pulmonary dysfunction 51, 53
- Post-perfusion syndrome 35
- Primary barrier 4–10
- Prostacyclin (PGI_2) 102, 110, 111, 114
- Protein effect 16–17
- Pulmonary arterial occlusion pressure (PAOP) 231, 232
- Pulmonary blood flow 145–7
- Pulmonary capillary pressure 181
- Pulmonary capillary wedge pressure (PCWP) 80, 81, 84
- Pulmonary contusion 22
- Pulmonary failure 45
- scoring system 215
- Pulmonary fibrosis 30
- Pulmonary hypertension 193
- Pulmonary leucostasis 25, 38
- Pulmonary membrane damage 38–9
- Pulmonary microemboli 45
- Pulmonary vascular resistance 55, 57, 126
- Respiratory circuit 173
- Respiratory failure 139, 143
- Respiratory support 139–52
- Reticuloendothelial system 62
- Right coronary artery blood flow 127
- Right ventricular contraction pattern 127
- Right ventricular ejection fraction (RVEF) 84–6
- Right ventricular end diastolic volume (RVEDV) 81, 85–6
- and filling pressure 125–6

- Right ventricular failure 84–6
 Right ventricular performance 125–9
 Rotating disc valve catheter 159, 163
- Salmonella abortus equi* endotoxin 185
 Sapheno-saphenous cannulation 172
 Screen filtration pressure (SFP) 46, 47, 50, 51, 56
 Secondary barrier 10–13
 Septic shock/septicaemic shock 200
 haemodynamic concepts in 79–93
 hyperdynamic state in 184, 192
 low flow states 193
 myocardial depression in 86–9
 pathophysiology of 179–84
 vasoactive agents in 191–6
 volume support in 183–4
 Series inhomogeneity 143
 Severe combined acute renal and respiratory failure (SCARRF) 226
 Shock 43–5
 model of 45–50, 55–9
 use of term 43
 “Shock cocktails” 97
 Shock lung 27–30, 43–5
 acute stage 28
 aetiology of 44
 causes of 44
 development of 53
 pathophysiology of 59–62
 prognosis of 44
 subacute stage 30
 use of term 43
 Spontaneous breathing 150–2
- Starling balance 3, 13
 Starling forces 3–4
 Stratified inhomogeneity 143
 Surgical shock model 45–50, 55–9
 Swan–Ganz catheterization 147
- Therapeutic Intervention Scoring System (TISS) 214
 Tissue hypoxia in the critically ill 98–9
 Transendothelial hydrodynamic state 3
 Transmembranous fluid exchange imbalance 180–3
 Transparenchymal carbon dioxide counterflow 159, 163
 TXA₂ 114, 115
 TXB₂ 114
- Vasoactive agents
 choice of 193–5
 in septic shock 191–6
 Ventilation modes 147–8
 Ventilation–perfusion mismatch 153–6
 Ventilatory support 139–52
 Ventricular diameter 133
 Ventricular interference 126, 128–33
 Ventricular pressures 133
 Vesicles 7–8
- White cell activation 37–8
 Whole body inflammatory response hypothesis 35–6